Cost–utility analysis of mogamulizumab in advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma

AIM: This study assessed the cost–utility of mogamulizumab, a novel monoclonal antibody, versus established clinical management (ECM) in UK patients in previously treated advanced mycosis fungoides (MF)/Sézary syndrome (SS). MATERIALS & METHODS: Lifetime partitioned survival model based on overa...

Descripción completa

Detalles Bibliográficos
Autores principales: Muszbek, Noemi, Remak, Edit, Xin, Qian, McNamara, Linda, Jones, Trefor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Becaris Publishing Ltd 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508303/
https://www.ncbi.nlm.nih.gov/pubmed/37338181
http://dx.doi.org/10.57264/cer-2023-0028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508303/
https://www.ncbi.nlm.nih.gov/pubmed/37338181
http://dx.doi.org/10.57264/cer-2023-0028

Ejemplares similares